Shiyang Zhang^1,#, Jingchen Li^1,#, Qianxu Jin², Siyu Zhu¹, Hongshan Yan², Yizheng Wang³, Zihan Song¹, Liqiang Liu^1,*

Oncology Research, Vol.33, No.10, pp. 2961-2979, 2025, DOI:10.32604/or.2025.064300 - 26 September 2025

Abstract Background: Glioma is the most common tumor of the central nervous system with a poor prognosis. This study aims to explore the role of calcium/calmodulin-dependent protein kinase IIβ (CAMK2B) in regulating the malignant progression of glioma cells, as well as the molecular mechanisms underlying these malignant behaviors. Methods: The correlation between CAMK2B expression in gliomas and patient prognosis was analyzed using immunohistochemistry, quantitative reverse transcription polymerase chain reaction (qRT-PCR), and western blot. Furthermore, the study explored the role of CAMK2B in glioma cell proliferation, invasion, and migration using cell counting kit-8 (CCK-8), 5-Ethynyl-2^′-deoxyuridine (EdU), wound healing,… More >

ANGUO WU^1,#, JIAO YAN^2,3,#, TING SU^2,4, CHI FENG¹, XIN LONG^5,6, YIRU PAN¹, RUPEI YE², TIAN XIA², HANAN LONG², JIANMING WU^1,*, XIULI XIAO^2,*

Oncology Research, Vol.32, No.7, pp. 1197-1207, 2024, DOI:10.32604/or.2024.046139 - 20 June 2024

Abstract Breast cancer, a predominant global health issue, requires ongoing exploration of new therapeutic strategies. Palbociclib (PAL), a well-known cyclin-dependent kinase (CDK) inhibitor, plays a critical role in breast cancer treatment. While its efficacy is recognized, the interplay between PAL and cellular autophagy, particularly in the context of the RAF/MEK/ERK signaling pathway, remains insufficiently explored. This study investigates PAL’s inhibitory effects on breast cancer using both in vitro (MCF7 and MDA-MB-468 cells) and in vivo (tumor-bearing nude mice) models. Aimed at elucidating the impact of PAL on autophagic processes and exploring the potential of combining it with trametinib… More > Graphic Abstract

Rui Jiang^*, Chao Zhang^†, Guangyao Liu^*, Rui Gu^*, Han Wu^*

Oncology Research, Vol.25, No.8, pp. 1409-1419, 2017, DOI:10.3727/096504017X14882829077237

Abstract Osteosarcoma is the most common primary bone malignancy manifested predominantly in children and young adults. Studies indicate that miR-107 is involved in the pathogenesis of osteosarcoma and that tropomyosin 1 (TPM1) acts as a tumor suppressor in many types of cancer. In this study, we analyzed the effect of miR-107 on human osteosarcoma cells and investigated the mechanism in which TPM1 is involved. miR-107 expression in human osteosarcoma tissues and cells was analyzed in quantitative real-time PCR (qRT-PCR). Human osteosarcoma (U2OS) cells were transfected with miR-107 mimic, inhibitor, or scramble controls to evaluate the effect… More >